Business
IMC Presentation on Board Changes
IMC Presentation on Board Changes.
About this update from Physiomics Plc
[{"type":"text","content":"\n\n15 October 2024\n \nPhysiomics plc\n(\"Physiomics\" or the \"Company\")\n \nIMC Presentation on Company Website\n \nPhysiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, recently provided a brief update in-line with its End of Year results via Investor Meet Company and has updated its website with the presentation.\n \nThe presentation and Q&A from the meeting are now available at the Company's website:\nhttps://www.physiomics.co.uk/portfolio-item/investor-presentation-full-year-results-and-company-update/\n \n \nEnquiries:\n \nPhysiomics plc\nDr Jim Millen, Non-Executive Chairman\nDr Peter Sargent, Chief Executive Officer\n+44 (0)1235 841575\n \nHybridan LLP (Broker)\nClaire Louise Noyce\n+44 (0) 203 764 2341\n \nStrand Hanson Ltd (NOMAD)\nJames Dance & James Bellman\n+44 (0)20 7409 3494\n \n \nNotes to Editor\n \nAbout Physiomics\n \nPhysiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.\n \n\n","length":3721,"tagName":"div"}]